Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
about
Bortezomib for the treatment of multiple myelomaBortezomib for the treatment of mantle cell lymphoma: an updateCurrent Trends of Renal Impairment in Multiple MyelomaMultiple myeloma in the very elderly patient: challenges and solutionsEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexitySubcutaneous Administration of Bortezomib: A Pilot Survey of Oncology NursesNovel strategies to target the ubiquitin proteasome system in multiple myelomaSpotlight on ixazomib: potential in the treatment of multiple myelomaNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementManagement of mantle cell lymphoma in the elderly patientInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationEuropean perspective on multiple myeloma treatment strategies in 2014Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesValidation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximabA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceAAPT Diagnostic Criteria for Chronic Cancer Pain ConditionsClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsUtilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myelomaThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaBortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
P2860
Q24185881-459D46D0-2075-42A8-8005-7C2368A36149Q26738940-63041308-C69C-4FBC-9E16-67039AA7EDD3Q26740444-C74C62E0-D02F-4D08-891D-8662884558F2Q26752991-762B7C73-D9C7-48C4-9945-CCC72EDAA8A8Q26771331-411DA442-EC5C-419D-AADC-CA8C1EE4AF96Q26771947-F26DBDDB-038E-4B17-A87D-FF280D8C1601Q26773246-9DABFA9A-5D5B-44B4-A87D-09EABDF2A6F8Q26774440-1BEF5287-C026-43AD-8495-0D6CD6D4739BQ26822754-ED2C2F6F-53BC-4D8A-9E84-44198D87A439Q26851202-BC3B3452-7E58-4CD3-8AAB-3167B9BB3E69Q26862828-0D124063-ABC2-4804-990B-9AC531344B38Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62Q26999395-749430C0-9516-4874-9B3B-96838E412585Q27002668-7BF69572-6CD4-4078-8110-69D32ADB27F9Q27005966-8D92004C-6FCD-404E-A6C9-3934C4594073Q27026478-F361F8A7-6BE7-47B7-A15D-0EA537B23C5CQ27336141-43BA9282-64C7-44E0-A36A-A79B327CCAA6Q28067148-43BBCEC5-F511-4F47-BF62-C5C9ED57743AQ28077567-E51BD897-9DAC-4703-A1B5-2A12C65F4D15Q28079708-F361C6E4-11A9-42A5-827D-FE9D927EC02DQ28080999-0975FC0B-3BF5-4865-9324-1409C51B43CDQ28082910-80C92428-AA69-4E40-B87F-202F085BFB17Q28084683-45241346-2946-4A5B-881F-19513DB5A7BCQ28544663-FA16C208-52A6-400A-B171-AA06801C4CFAQ30248842-5DD0BE31-2395-427C-8744-5E22A8B55311Q30313340-DF96FA76-BD46-4C9D-91BD-A7FB32FB7C3EQ30964688-77842B8D-4EAB-4D5E-8179-1FCA6E50318CQ31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2BQ33402536-70E47174-F833-46B9-B887-5EC0AC04AA5DQ33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7Q33405181-ED527469-4FA1-45E0-A831-77B9B5C4285FQ33406992-9218AAB1-9653-44C8-802F-2882752CB8B3Q33408049-690044C3-11AB-458D-88B6-179E3DD7DA80Q33408056-7E218F63-4321-442B-8A59-601DE9614F34Q33409172-2CA28164-75FC-4952-B471-444F054C2CFCQ33409681-D34276FA-5CC0-4E11-8A46-9ED7B205DC08Q33410213-CE3BEA7A-0433-4B47-8F68-3F752B23F8C5Q33410637-A89C2865-4B19-489D-975B-AC68497CE985Q33411100-1BB56D68-6437-478D-835A-E55663FE67F9Q33411708-8BB71466-89BD-438C-B5AC-150DEE108F30
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@ast
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@en
type
label
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@ast
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@en
prefLabel
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@ast
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@en
P2093
P1433
P1476
Subcutaneous versus intravenou ...... hase 3, non-inferiority study.
@en
P2093
Anna Shubina
Bertrand Arnulf
Dixie-Lee Esseltine
Grigoriy Rekhtman
Halyna Pylypenko
Helgi van de Velde
Huaibao Feng
Ievgenii Karamanesht
James Cavet
Jean-Luc Harousseau
P304
P356
10.1016/S1470-2045(11)70081-X
P577
2011-04-18T00:00:00Z